Prostate Screening Saved My Life – Is This Really True for Most Patients?
In this article
Understanding the delicate balance between the validity of a patient's claim that «PSA screening saved my life» and science's statistical skepticism.
The slogan «PSA screening saved my life!», which recently appeared even in 2026 Super Bowl advertisements, drew both praise and strong criticism from the oncology community. Although this emotional statement may be true for an individual, experts examining the 23-year data from the European Randomized Study of Screening for Prostate Cancer (ERSPC) emphasize that no clear overall survival advantage has been demonstrated. Why, then, is consensus so elusive?
PSA: the secrets beyond a protein
PSA is a tissue-specific protein that reflects both benign and malignant changes in prostate tissue. Although an excellent tool for monitoring treatment response in advanced prostate cancer, its use in screening also reveals tumors that are «lying quietly» and pose no threat to life.
What makes matters more complicated is that the most dangerous types, such as neuroendocrine prostate cancer, generally do not produce PSA. This reminds us once again that PSA is not merely a «numerical value», but a «biological clue» that must be interpreted correctly.
The endless debate: arguments for and against
Supporters of screening
- Early diagnosis increases the chance of curative surgery.
- A proportional decline in prostate cancer deaths has been observed in the post-PSA era.
- Some randomized studies have shown a reduction in disease-specific deaths in the screened arms.
- Without screening, many patients might be diagnosed only once bone metastases develop.
The skeptics
- A significant increase in overall survival, or total lifespan, has not been proven.
- Overdiagnosis: Aggressive treatments for tumors that would never cause problems leave permanent damage.
- Treatment adverse effects, including urinary incontinence and erectile dysfunction, often outweigh the benefits.
- The ProtecT study involving 82 thousand people in England did not identify a clear survival advantage in the real world.
A statistical illusion: why do deaths not fall as case numbers rise?
Prostate cancer is an extremely heterogeneous disease. Many men can live for decades with some cancer cells in the prostate without any health problems. As screening became more widespread, we effectively discovered this «silent reservoir». The real danger, however, lies in rapidly progressing variants.
Annual Prostate Cancer Deaths in the United States
1989: 25943 Deaths
2011: 28170 Deaths
2025: 33500 Deaths
The fact that absolute death counts have not fallen despite such widespread screening demonstrates that screening alone is not a solution; instead, precise patient selection is necessary.
Screening programs often inadequately represent high-risk individuals, including African Americans and those with a family history. A responsible physician should base the decision not simply on a laboratory report, but on the patient's genetics and life expectancy.
Healing begins with the right question
Prof. Dr. Mustafa Özdoğan & Dr. Önder Kırca
On our healing journey with cancer, our greatest guide is «conscious awareness». A PSA test is neither a hero nor an enemy in itself; it is simply a technical compass in our hands. What matters is for whom, when and how we use that compass.
Instead of imposing a standard template on every man, we must now build a dialogue centered on the patient's risk profile, family tree and, above all, «quality of life». «Saving lives» means more than postponing death: it also means preserving healthy years with dignity and comfort. The PSA debate reminds us that medicine's future lies not in more testing, but in a deeper and more precise understanding. Healing means hearing the patient's voice and sharing in the right decision.
Scientific sources and references
- 1. Raghavan D, Tannock IF. "European Study of Prostate Cancer Screening – 23-year follow-up." N Engl J Med 2026;394:410.
- 2. Roobol MJ, et al. "European Study of Prostate Cancer Screening—23-year follow-up." N Engl J Med 2025;393:1669-1680.
- 3. Hamdy FC, et al. "Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer (ProtecT trial)." N Engl J Med 2023;388:1547-1558.
- 4. USPSTF: Screening for prostate cancer recommendation statement. JAMA 2018;319:1901-1913.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.